Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.53 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | KAT7 | O95251 | 1/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16614219 | 0.87 | DRD4 (0.53) | DRD4SIGMAR1TMEM97 | |
| SCHEMBL27471148 | 0.84 | PRMT5 (0.52) | PRMT5WDR77KAT7KAT8PDE4B | |
| SCHEMBL29136116 | 0.84 | PRMT5 (0.50) | PRMT5WDR77PDE4B | |
| SCHEMBL6413520 | 0.83 | DRD4 (0.53) | DRD4BCL9CTNNB1SIGMAR1TMEM97 | |
| SCHEMBL29117319 | 0.83 | PRMT5 (0.56) | PRMT5WDR77KAT7KAT8 | |
| SCHEMBL12607070 | 0.83 | PRMT5 (0.56) | PRMT5WDR77KAT7KAT8 | |
| SCHEMBL12607067 | 0.83 | PRMT5 (0.56) | PRMT5WDR77KAT7KAT8 | |
| SCHEMBL2069058 | 0.83 | MEN1 (0.48) | PRMT5WDR77 | |
| SCHEMBL23839391 | 0.81 | LIPG (0.49) | PRMT5WDR77 | |
| SCHEMBL21668749 | 0.81 | LIPG (0.49) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494992-B2 | Antiparasitic terpene alkaloids | PFIZER INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | PFIZER PRODUCTS INC | 2007-08-09 | — | — | US | disclosed |
| EP-1597264-A2 | ANTIPARASITIC TERPENE ALKALOIDS | Pfizer Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072086-A2 | ANTIPARASITIC TERPENE ALKALOIDS | PFIZER LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185101-A1 | Antiparasitic terpene alkaloids | CYP51A1, DHPS, CYP8B1 | DRD4 185/4885BCL9 3832/4885CTNNB1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.